Targeting MHC class I monomers to dendritic cells inhibits the indirect pathway of allorecognition and the production of IgG alloantibodies leading to long-term allograft survival.
T cell depletion strategies are an efficient therapy for the treatment of acute rejections and are an essential part of tolerance induction protocols in various animal models; however, they are usually nonselective and cause wholesale T cell depletion leaving the individual in a severely immunocompromised state. So far it has been difficult to selectively delete alloreactive T cells because the majority of protocols either delete all T cells, subsets of T cells, or subpopulations of T cells expressing certain activation markers, ignoring the Ag specificity of the TCR. We have developed a model in which we were able to selectively deplete alloreactive T cells with an indirect specificity by targeting intact MHC molecules to quiescent dendritic cells using 33D1 as the targeting Ab. This strategy enabled us to inhibit the indirect alloresponse against MHC-mismatched skin grafts and hence the generation of IgG alloantibodies, which depends on indirectly activated T cells. In combination with the temporary abrogation of the direct alloresponse, we were able to induce indefinite skin graft survival. Importantly, the targeting strategy had no detrimental effect on CD4(+)CD25(+)FoxP3(+) T cells, which could potentially be used as an adjunctive cellular therapy. Transplantation tolerance depends on the right balance between depletion and regulation. For the former this approach may be a useful tool in the development of future tolerance induction protocols in non-sensitized patients.
Tanriver
Yakup
Y
Medical Research Council Center for Transplantation, King's College London, School of Medicine, Guy's Hospital, London, UK.
Ratnasothy
Kulachelvy
K
Bucy
R Pat
RP
Lombardi
Giovanna
G
Lechler
Robert
R
D019264:Adoptive Transfer; D000595:Amino Acid Sequence; D000818:Animals; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006084:Graft Rejection / Q000276:immunology*; D006085:Graft Survival / Q000276:immunology; D006183:H-2 Antigens / Q000276:immunology / Q000378:metabolism*; D007074:Immunoglobulin G / Q000096:biosynthesis*; D007518:Isoantibodies / Q000096:biosynthesis*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D015398:Signal Transduction / Q000276:immunology*; D016038:Skin Transplantation / Q000276:immunology*; D013601:T-Lymphocytes / Q000637:transplantation; D023001:Transplantation Tolerance
D006183:H-2 Antigens; C024755:H-2K(K) antigen; D007074:Immunoglobulin G; D007518:Isoantibodies